Citi Pharma (KAR:CPHL) Stock Based Compensation: ₨0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨74.68
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Stock Based Compensation?

Citi Pharma KAR:CPHL +0.69% 15 Stock Based Compensation is ₨0.00 Mil as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Citi Pharma's Stock Based Compensation for the six months ended in . 20 was ₨0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was ₨0.00 Mil.

Citi Pharma Stock Based Compensation Related Terms

Citi Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Stock Based Compensation Chart

Citi Pharma Annual Data
Trend
Stock Based Compensation

Citi Pharma Semi-Annual Data
Stock Based Compensation
KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was ₨0.00 Mil.

What does a Stock Based Compensation of ₨0.00 Mil mean?
Citi Pharma (KAR:CPHL) has a Stock Based Compensation of ₨0.00 Mil as of . 20. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Citi Pharma and its competitors.
Is Citi Pharma's Stock Based Compensation too high?
Citi Pharma's current Stock Based Compensation is ₨0.00 Mil. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Stock Based Compensation compare to ZTS and UTHR?
Citi Pharma's Stock Based Compensation of ₨0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Citi Pharma and its competitors. Citi Pharma's current Stock Based Compensation is ₨0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Stock Based Compensation of ₨0.00 Mil. The current Stock Based Compensation is ₨0.00 Mil. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Stock Based Compensation is ₨0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨74.68
Price